⌕
Iovance Biotherapeutics · IOVA · Nasdaq
Tenet 52 · Mixed
Compare
$7.55−2.71%At closeTenet 52 · Mixed
$7.55−0.21 (−2.71%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Iovance Biotherapeutics (IOVA) Stock Checks

How IOVA measures up against value, income, timing, and long-hold tenets. Every criterion shows the number as of the last close and the pass rule. Always free.

Sources Company filings and computed by Tenet Filings and TenetScreens as of How we compute thisNot investment advice

The tenets below and the 0-100 Tenet Score on this report are two separate computations: each tenet runs its own criteria and its own pass rule, while the score is a percentile composite reported as one of four verdict words (Strong, Solid, Mixed or Weak).

1 / 17 qualify todayas of close, Nov 13, 2026 · computed nightly from our fundamentals DB; point-in-time auditable.
QUALIFIES
1
meet every gate today
BORDERLINE
3
within one input of the gate
FAILS
8
miss at least one gate
UNKNOWN
5
insufficient data to judge
Buffett Qualitydurable moat
✕ Fails
FailsROE ≥ 15%−29.1% · ≥ 15.0%
PassesGross margin ≥ 40%53.2% · ≥ 40.0%
FailsNet margin ≥ 15%−58.2% · ≥ 15.0%
PassesDebt/equity ≤ 0.50.00 · ≤ 0.50
FailsGrowing FCF (multi-yr)Free cash flow was negative in fiscal 2025.no · > 0
Decided by the pass rule for Buffett Quality.
The pass rule for Buffett Quality is what decides that verdict, and it is not restated here.Buffett Quality under The screens ›Today's Buffett Quality list ›
FailsReturn on assets positive−42.8% · > 0
FailsOperating cash flow positive−$302.4M · > 0
FailsReturn on assets improving−40.9% → −42.8%
PassesEarnings backed by cash (CFO > net income)−$302.4M vs −$391.0M
FailsLeverage falling (long-term debt / assets)We hold no record of long-term debt as a share of assets for both years for this company, so this signal could not be measured. It still scores 0 under this module's conservative rule (a point is never awarded without evidence), and it is not counted as one of the signals we were able to measure.0.1% → n/a
FailsCurrent ratio improving3.74 → 3.20
FailsNo share dilution (≤ +2%)+23.3%
FailsGross margin expanding43.2% → 34.3%
PassesAsset turnover improving0.18 → 0.29
Decided by the pass rule for Piotroski F-Score.
The pass rule for Piotroski F-Score is what decides that verdict, and it is not restated here. 1 of 9 carry no data.Piotroski F-Score under The screens ›Today's Piotroski F-Score list ›
Unknown — no dataROIC ≥ 15%— · ≥ 15.0%
Unknown — no dataNet debt/EBITDA ≤ 3×— · ≤ 3.0×
PassesAltman Z ≥ 3 (safe zone)8.09 · ≥ 3.00
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 3 checks below carry data.Munger Compounders under The screens ›Today's Munger Compounders list ›
FailsEBIT > 0−$230.4M · > 0
Unknown — no dataEarnings yield EBIT/EV ≥ 6%— · ≥ 6.0%
Unknown — no dataReturn on capital ≥ 25%— · ≥ 25.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 3 checks below carry data. The pass rule for Magic Formula is not published separately on the methodology page.About this screen ›Today's Magic Formula® list ›
PassesSize: market cap ≥ $2B$3.6B · ≥ $2.0B
PassesCurrent ratio ≥ 25.20 · ≥ 2.00
FailsPositive EPS 10y0y
FailsPays a dividend$0.00 · > 0
Unknown — no dataEPS growth ≥ 3%/yr— · ≥ 3.0%
Unknown — no dataP/E ≤ 15— · ≤ 15.00
Unknown — no dataP/E × P/B ≤ 22.5— · ≤ 22.50
Decided by the pass rule for Graham Defensive.
The pass rule for Graham Defensive is what decides that verdict, and it is not restated here. 3 of 7 carry no data.Graham Defensive under The screens ›Today's Graham Defensive list ›
Unknown — no dataPEG < 1 (hist. growth)— · < 1.00
Unknown — no dataEPS growth 10–30%— · 10.0%–30.0%
Verdict Unknown for this set.
Verdict Unknown for this set. None of the 2 checks below carry data.Lynch GARP under The screens ›Today's Lynch GARP list ›
FailsPays a dividend$0.00 · > 0
Unknown — no dataYield in a healthy band (not a yield trap)0.0% · 1.0%–8.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataEarnings payout not stretched— · ≤ 75.0%
Unknown — no dataBalance sheet can sustain the payout— · ≤ 4.0×
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 5 checks below carry data. The pass rule for Income & Dividend Safety is not published separately on the methodology page.
FailsPays a dividend$0.00 · > 0
Unknown — no dataAnnual dividend raised 10+ years running (Aristocrat ≥25, King ≥50)— · ≥ 10.00
Unknown — no dataNo dividend cut in the last 5 years—
Unknown — no data5-year dividend growth ≥ 5%/yr— · ≥ 5.0%
Unknown — no dataCovered by free cash flow— · ≥ 1.20
Unknown — no dataPayout not stretched— · ≤ 75.0%
Verdict Unknown for this set.
Verdict Unknown for this set. 1 of 6 checks below carry data.Dividend Growth under The screens ›Today's Dividend Growth list ›
FailsReturn on invested capital ≥ 15% in 4+ of the last 5 years0 of 5
Not scored: see the reason belowRevenue compounding ≥ 8%/yr over 5 yearsFive-year revenue history is incomplete in our data, so the compounding rate can't be computed yet.— · ≥ 8.0%
FailsNot diluting: diluted share count flat-to-down (≤ +1%/yr)19.2% · ≤ 1.0%
FailsFree cash flow margin ≥ 12%−57.0% · ≥ 12.0%
Not scored: see the reason belowEarnings backed by cash (operating cash flow ≥ net income)A loss year makes cash-vs-earnings unreadable: the ratio inverts over negative net income, so it is not scored (never counted against).— · ≥ 1.00
Reading: does not hold. Not a gate checkDisciplined buybacks: actively reducing the share count (bonus)reading, not a gate check19.2%
Decided by the pass rule for Quality Compounder.
The pass rule for Quality Compounder is what decides that verdict, and it is not restated here. 2 of 5 carry no data. Lines marked as readings are published beside the checks and are not gate checks.Quality Compounder under The screens ›Today's Quality Compounder list ›
FailsOff its 52-week high by 8–35% (a dip, not a collapse)49.5% · 8.0%–35.0%
FailsDip within its own normal pullback band0.50
FailsNot past where its dips have historically recovered from3.65
PassesA dip in an uptrend (above a rising 200-day)6.11
FailsHigher-low structure still intactstructure broken · higher low
Unknown — no dataClear of the earnings blackout (more than 5 days out)— · > 5.00
Decided by the pass rule for Drawdown Context.
The pass rule for Drawdown Context is what decides that verdict, and it is not published separately on the methodology page. 1 of 6 carry no data.
Unknown — no dataA bullish MACD cross within 10 sessions— · ≤ 10.00
FailsReclaimed a rising 50-day EMA10.33
PassesPrinted a higher lowyes
FailsA volume thrust on the turn (≥ 1.2× normal)0.72 · ≥ 1.20
FailsReversal signals fired: 3 of 4 (MACD·MA·HL·Vol)1.00 · ≥ 3.00
Decided by the pass rule for Reversal Evidence.
The pass rule for Reversal Evidence is what decides that verdict, and it is not published separately on the methodology page. 1 of 5 carry no data.
FailsIn the cheap half of its own 5-year valuation range0.8×
PassesEarnings estimates not being cut0.33
PassesReturns on capital not deteriorating−0.58
Decided by the pass rule for Not-a-Value-Trap Gate.
The pass rule for Not-a-Value-Trap Gate is what decides that verdict, and it is not published separately on the methodology page.
FailsOperating profit is positive−$230.4M · > 0
FailsReturn on invested capital ≥ 10%−28.3% · ≥ 10.0%
Not scored: see the reason belowA solvent balance sheet (Altman Z ≥ 1.8, net debt/EBITDA ≤ 4)Net debt / EBITDA cannot be read over non-positive EBITDA: the ratio flips sign, so a net-cash company prints a healthy-looking positive. Only the Altman Z half, shown beside this line, is measurable, so the test is left unscored rather than counted either way.8.1×
FailsQuality score ≥ 5030.70 · ≥ 50.00
Unknown — no dataRevenue growing over 5 years— · > 0
Decided by the pass rule for Quality Floor.
The pass rule for Quality Floor is what decides that verdict, and it is not published separately on the methodology page. 2 of 5 carry no data.
A research signal from published criteria, not a recommendation.
FailsDrawdown context49.5% off its 52-week high
FailsReversal evidence1 of 4 signals fired
FailsTrap gate2 of 3 held
FailsQuality floor0 of 5 held · 2 no data
Invalidation level (structure break): below this the dip's structure has broken$12.92
Decided by the pass rule for Qualified Dip.
The pass rule for Qualified Dip is what decides that verdict, and it is not restated here.Qualified Dip under The screens ›Today's Qualified Dip list ›
FailsTrading above its 50-day average11.33
PassesTrading above its 200-day average6.11
Passes50-day average above the 200-day (uptrend stack)11.33
Passes50-day average sloping up0.14 · > 0
Decided by the pass rule for Trend Alignment.
The pass rule for Trend Alignment is what decides that verdict, and it is not published separately on the methodology page.
Passes3-month return in the top half of the universe0.79 · ≥ 0.50
Passes12-minus-1 momentum in the top half of the universe1.00 · ≥ 0.50
PassesRelative strength vs the S&P 500 improving0.00 · > 0
PassesEarnings estimates being revised up0.33
Decided by the pass rule for Relative Strength.
The pass rule for Relative Strength is what decides that verdict, and it is not published separately on the methodology page.
FailsMACD above its signal line−1.32
Not scored: see the reason belowBack above the 50-day on a fresh cross (≤10 sessions)This is a two-part reading (price back above the 50-day, and a bullish momentum cross inside 10 sessions) and a dated momentum cross is not on record for this name yet, so it is left unscored rather than counted either way.—
PassesHigher high and higher low (stair-stepping up)higher high · higher low
FailsA volume thrust on the move (≥ 1.2× normal)0.72 · ≥ 1.20
Decided by the pass rule for Momentum Trigger.
The pass rule for Momentum Trigger is what decides that verdict, and it is not published separately on the methodology page. 1 of 4 carry no data.
Average daily swing: high0.12
Volatility band width: expanded (wide range)1.00
Distance from its 52-week high: a deep pullback0.50
Every verdict is auditableEach criterion shows the number as of the last close and the pass rule side by side: a receipt, not a rating. Several of these screens publish their rule in full under The screens; each row links to its own section where there is one.
Unknown ≠ failAn “— Unknown” verdict means the inputs were insufficient: context, not a signal, and never counted as a fail.

How many investing rule sets does Iovance Biotherapeutics pass?

Iovance Biotherapeutics qualifies on 1 of 17 rule sets as of 2026-11-13, with 3 borderline and 8 failing.

Does Iovance Biotherapeutics meet the Graham Defensive criteria?

Iovance Biotherapeutics fails the Graham Defensive rule set as of 2026-11-13.

Does Iovance Biotherapeutics meet the Buffett Quality criteria?

Iovance Biotherapeutics fails the Buffett Quality rule set as of 2026-11-13.

Computed from our fundamentals DB; historical-CAGR PEG basis for Lynch. Research, not investment advice. Tenet's rulesets are independently developed from publicly available sources, and Tenet is not affiliated with, sponsored by, endorsed by or otherwise associated with any referenced investor or trademark owner. Full notice. MAGIC FORMULA is a trademark of MagicFormulaInvesting.com LLC.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.